Copertina

Reinduction of hedgehog inhibitors after checkpoint inhibition in advanced basal cell carcinoma: a series of 12 patients

For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.

Salvato in:
Dettagli Bibliografici
Autori principali: DeTemple, Viola (Autore) , Hassel, Jessica C. (Autore) , Sachse, Michael M. (Autore) , Grimmelmann, Imke (Autore) , Leiter, Ulrike (Autore) , Gebhardt, Christoffer (Autore) , Eckardt, Julia (Autore) , Pföhler, Claudia (Autore) , Angela, Yenny (Autore) , Hübbe, Hanna (Autore) , Gutzmer, Ralf (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: 7 November 2022
In: Cancers
Year: 2022, Volume: 14, Fascicolo: 21, Pages: 1-9
ISSN:2072-6694
DOI:10.3390/cancers14215469
Accesso online:Resolving-System, Volltext: https://doi.org/10.3390/cancers14215469
Verlag, Volltext: https://www.mdpi.com/2072-6694/14/21/5469
Testo
Note sull'autore:Viola K. DeTemple, Jessica C. Hassel, Michael M. Sachse, Imke Grimmelmann, Ulrike Leiter, Christoffer Gebhardt, Julia Eckardt, Claudia Pföhler, Yenny Angela, Hanna Hübbe and Ralf Gutzmer
Descrizione
Riassunto:For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure.
Descrizione del documento:Gesehen am 26.01.2023
Descrizione fisica:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14215469

Documenti analoghi